Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
369.19 ^USD	+1.52%		-3.94%	+12.80%

02-12	Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM
02-12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE

RBC Raises Price Target on Amgen to $335 From $330, Keeps Outperform Rating

Published on 01/08/2026 at 12:16 pm GMT

MT Newswires

Latest news about Amgen Inc.

02-12	Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM
02-12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE
02-12	European Commission Approves Amgen's UPLIZNA for Generalized Myasthenia Gravis	CI
02-10	Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating	MT
02-06	Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating	MT
02-04	Health Care Up After Eli Lilly Earnings -- Health Care Roundup	DJ
02-04	TD Cowen Adjusts Price Target on Amgen to $420 From $389, Maintains Buy Rating	MT
02-04	Leerink Partners Adjusts Price Target on Amgen to $355 From $305, Maintains Market Perform Rating	MT
02-04	RBC Raises Price Target on Amgen to $360 From $335, Keeps Outperform Rating	MT
02-04	Morgan Stanley Raises Price Target on Amgen to $309 From $304, Keeps Equalweight Rating	MT
02-03	Amgen posts Q4 total revenue $9.87 bln vs IBES estimate $9.47 bln	RE
02-03	Amgen Inc., Q4 2025 Earnings Call, Feb 03, 2026
02-03	Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026	CI
02-03	Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost	DJ
02-03	Amgen Q4 Adjusted Earnings Fall, Revenue Rises; Issues Guidance	MT

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.4% of net sales.

Employees

28,000

Sector

Pharmaceuticals

Calendar

04-28 - Q1 2026 Earnings Release (Projected)

More about the company